Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 12:12:578708.
doi: 10.3389/fphys.2021.578708. eCollection 2021.

The Affinity of Hemoglobin for Oxygen Is Not Altered During COVID-19

Affiliations

The Affinity of Hemoglobin for Oxygen Is Not Altered During COVID-19

Thomas Gille et al. Front Physiol. .

Abstract

Background: A computational proteomic analysis suggested that SARS-CoV-2 might bind to hemoglobin (Hb). The authors hypothesized that this phenomenon could result in a decreased oxygen (O2) binding and lead to hemolytic anemia as well. The aim of this work was to investigate whether the affinity of Hb for O2 was altered during COVID-19. Methods: In this retrospective, observational, single-center study, the blood gas analyses of 100 COVID-19 patients were compared to those of 100 non-COVID-19 patients. Fifty-five patients with carboxyhemoglobin (HbCO) ≥8% and 30 with sickle cell disease (SCD) were also included ("positive controls" with abnormal Hb affinity). P50 was corrected for body temperature, pH, and PCO2. Results: Patients did not differ statistically for age or sex ratio in COVID-19 and non-COVID-19 groups. Median P50 at baseline was 26 mmHg [25.2-26.8] vs. 25.9 mmHg [24-27.3], respectively (p = 0.42). As expected, P50 was 22.5 mmHg [21.6-23.8] in the high HbCO group and 29.3 mmHg [27-31.5] in the SCD group (p < 0.0001). Whatever the disease severity, samples from COVID-19 to non-COVID-19 groups were distributed on the standard O2-Hb dissociation curve. When considering the time-course of P50 between days 1 and 18 in both groups, no significant difference was observed. Median Hb concentration at baseline was 14 g.dl-1 [12.6-15.2] in the COVID-19 group vs. 13.2 g.dl-1 [11.4-14.7] in the non-COVID-19 group (p = 0.006). Among the 24 COVID-19 patients displaying anemia, none of them exhibited obvious biological hemolysis. Conclusion: There was no biological argument to support the hypothesis that SARS-CoV-2 could alter O2 binding to Hb.

Keywords: COVID-19; P50; SARS-CoV-2; anemia; gas exchange; gas transport; hemoglobin-oxygen affinity; hemolysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) Raw oxyhemoglobin (HbO2) in relation to PO2 in the COVID-19 group (red dots, 100 patients, 253 samples) and the non-COVID-19 group (blue dots, 100 patients, 221 samples). (B) Standardized HbO2 (Std-HbO2) in relation to PO2 in the COVID-19 group, according to the level of oxygen therapy (light red triangles: ambient air; medium red dots: O2 between 1 and 6 l.min− 1; dark red triangles: O2 ≥ 7 l.min− 1 or ventilation). Measured HbO2 was standardized for normal conditions (temperature = 37°C; pH = 7.4; PCO2 = 40 mmHg) in order to compare it to the predicted HbO2 given by the standard O2-Hb dissociation curve, represented in black. (C) Std-HbO2 for normal conditions in relation to PO2 in the non-COVID-19 group, according to the level of oxygen therapy (light blue triangles: ambient air; medium blue dots: O2 between 1 and 6 l.min− 1; dark blue triangles: O2 ≥ 7 l.min− 1 or ventilation).
FIGURE 2
FIGURE 2
Time-course of mean P50 in the COVID-19 group (red circles) and the non-COVID-19 group (blue squares). Some days were regrouped to have sufficient number of samples (D810: n = 15 in the COVID-19 group and n = 10 in the non-COVID-19 group; D1115: n = 11 in both groups; D1618: n = 4 and n = 6, respectively). Data are presented as means and SE.

Similar articles

Cited by

References

    1. Afra T. P., Nampoothiri R. V., Razmi T. M., Hafi N. A. B. (2020a). Linking hydroxychloroquine to hemolysis in a ‘suspected’ glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection – a critical appraisal. Eur. J. Intern. Med. 80 101–102. 10.1016/j.ejim.2020.07.001 - DOI - PMC - PubMed
    1. Afra T. P., Vasudevan Nampoothiri R., Razmi T. M. (2020b). Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase-deficient patient with COVID-19 infection. Eur. J. Haematol. 105 512–513. 10.1111/ejh.13460 - DOI - PMC - PubMed
    1. Aguilar J., Averbukh Y. (2020). Hemolytic anemia in a glucose-6-phosphate dehydrogenase-deficient patient receiving hydroxychloroquine for COVID-19: a case report. Perm. J. 24:20.158. 10.7812/TPP/20.158 - DOI - PMC - PubMed
    1. Algassim A. A., Elghazaly A. A., Alnahdi A. S., Mohammed-Rahim O. M., Alanazi A. G., Aldhuwayhi N. A., et al. (2021). Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. Ann. Hematol. 100 37–43. 10.1007/s00277-020-04256-3 - DOI - PMC - PubMed
    1. Alnor A., Sandberg M. B., Gils C., Vinholt P. J. (2020). Laboratory tests and outcome for patients with COVID-19: a systematic review and meta-analysis. J. Appl. Lab. Med. 5 1038–1049. 10.1093/jalm/jfaa098 - DOI - PMC - PubMed